Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

A pyrrolo-pyrazole or pyrazolo-azepine derivative represented by formula (I):

• wherein R represents hydrogen or halogen atom, or an optionally substituted group selected from aryl C2-C6 alkenyl, (heterocyclyl)C2-C6 alkenyl, aryl C2-C6 alkynyl, or (heterocyclyl)C2-C6 alkynyl group, —R′, —COR′, —COOR′, —CN, —CONR′R″, —OR′, —S(O)qR′, —SO2NR′R″, —B(OR′″)2, —SnR″″, wherein R′ and R″, the same or different, independently represent hydrogen atom or an optionally further substituted straight or branched C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, saturated or unsaturated C3-C6 cycloalkyl, aryl, heterocyclyl, aryl C1-C6 alkyl or (heterocyclyl)C1-C6 alkyl;
• R′″ represents hydrogen, C1-C6 alkyl, or R′″, together with the two oxygen and the boron atoms, forms a saturated or unsaturated C5-C8 (hetero)cycloalkyl, optionally benzocondensed or substituted, and R″″ represents C1-C6 alkyl;
• R1 represents hydrogen atom or an optionally substituted group selected from —R′, —CH2R′, —COR′, —COOR′, —CONR′R″, C(═NH)NHR′, —S(O)qR′, or —SO2NR′R″, wherein R′ and R″ are as defined above;
• R2 represents hydrogen atom, —COR′, —COOR′, —CONR′R″, —S(O)qR′, —SO2NR′R″, C1-C6 alkyl or (heterocyclyl)C1-C6 alkyl group, wherein R′ and R″ are as defined above;
• Ra, Rb, Rc and Rd, being the same or different, independently represent hydrogen atom, an optionally further substituted straight or branched C1-C6 alkyl, aryl, heterocyclyl, aryl C1-C6 alkyl, (heterocyclyl)C1-C6 alkyl or —CH2OR′ group, wherein R′ is as above defined, or Ra Rb and/or Rc and Rd, taken together with the carbon atom to which they are bonded, form an optionally substituted, saturated or unsaturated, C3-C6 cycloalkyl group;
• q is 0, 1 or 2;
• m and n, each independently, represents 0, 1 or 2, provided that m +n is 0 or equal to 2 and with the following further provisos:
• when m and n are both 1, R is hydrogen atom or hydroxy group and Ra, Rb, Rc and Rd are all hydrogen atoms, then R1 is not hydrogen atom, acetyl, benzyl or ethoxycarbonyl group;
• when m is 2 and n is 0, R, Ra, Rb, Rc and Rd are all hydrogen atoms, then R1 is not hydrogen atom or ethoxycarbonyl group;
• when m and n are both 0, R, Ra, Rb, Rc and Rd are all hydrogen atoms, then R1 is not hydrogen atom, phenyl-oxazoldinone, quinoline, pyridobenzoxazine or naphtyridine group;
• when m and n are both 0, R is propyl, Ra, Rb, Rc and Rd are all hydrogen atoms, then R1 is not phenyl-oxazoldinone group and
• when m and n are both 0, R is hydroxy, methyl or ethyl group and Ra, Rb, Rc and Rd are all hydrogen atoms, then R1 is not a methoxycarbonyl group;
• or a pharmaceutically acceptable salt thereof